StemCells Inc.

StemCells Inc. is engaged in the research and development of cell-based therapeutics. The company's proprietary HuCNS-SC cells (purified human neural stem cells) are currently in development as a potential treatment for a broad range of central nervous system disorders. The company is currently conducting phase 1/2 clinical trials in chronic spinal cord injury and dry age-related macular degeneration. StemCells Inc. is also pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine. The company markets stem cell research products, including media and reagents, under the SC Proven brand.

Expert Comments:

Jason Kolbert, Maxim Group (3/17/15)
"StemCells Inc. closed the year with $25M in cash. . .2015 represents a 'proof of concept' year for the company, and on good data, we should see a value inflection."

Jason Kolbert, Maxim Group (3/9/15)
"We see StemCells Inc. as the leader in the allogeneic, fetal-derived stem cell space; the company is working to move the field beyond the trophic effects of mesenchymal cells in central nervous system disorders. Two exciting indications are in Phase 2 proof-of-concept studies now: spinal cord paralysis and dry age-related macular degeneration."

Katherine Genis, Edison Investment Research (1/7/15)
"StemCells Inc.'s human neural stem cells (HuCNS-SC) are currently in clinical trials for dry age-related macular degeneration (AMD) and spinal cord injuries; a Phase 2 study program in both indications is underway, following early signs of efficacy in Phase 1/2 trials. Dry AMD could be a sizeable opportunity (we estimate $2B in peak sales) and represents the bulk of our overall valuation of the company at $189M, or $2.75/share."

Jason Kolbert, Maxim Group (12/22/14)
"StemCells Inc. announced that the first patient in the Phase 2 Pathway study in cervical spinal cord injury (SCI) was transplanted with its proprietary HuCNS-SCs (purified human neural stem cells). . .the primary endpoints will assess changes in patient upper extremity strength as measured in the hands, arms and shoulders. . .in May of 2014, enrollment and dosing of 12 SCI patients as part of a phase I/II study was completed. . .combined with a favorable safety profile this early data is suggestive that HuCNS-SCs have efficacy in SCI. . .our metrics may prove conservative as the company approaches mature proof-of-concept data."

"StemCells Inc. held its first analyst day event on Nov. 20. One of the biggest questions was whether the company would be able to produce its cell-based therapeutic, HuCNS-SC (purified adult human neuronal cells of fetal origin), to scale. HuCNS-SC is a central nervous system-based therapeutic that differentiates into multiple cell lines—neural cells, glial cells and astrocytes. The company does have the ability, at least based on our conversations, to produce billions of cells at both Phase 3 clinical and commercial levels. . .

I definitely think there is extraordinary upside potential on this name, and there are meaningful milestones to get this stock to my target price of $6/share within the next 24 months." read more >

Stephen Dunn, LifeTech Capital (11/17/14)
"StemCells Inc. initiated a controlled Phase 2 trial ('the Pathway Study') of its HuCNS-SC in cervical spinal cord injury patients. . .the patients will be randomized to either a HuCNS-SC treatment arm or a nontreatment arm with blinded outcome assessment in approximately 12 centers in North America. It is expected to complete enrollment within one year."

More Comments

Experts Commenting on This Company

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
StemCells Inc. Content